Baird analyst Brian Skorney weighed in on Amgen (NASDAQ: AMGN) following disappointing Repatha outcomes data. The firm maintained a Neutral ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE